Jun-Ling Li (Junling Li, J Li)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 28

Top Topics

Small Cell Lung Cancer

Epidermal Growth Factor Receptor

Top Venues

Thoracic cancer

Journal of cancer research and clinical oncology

Cancer innovation

Molecular cancer research : MCR

This page only lists publications with an associated author ORCID identifier.

Publications

Ziyi Xu, Zihua Zou, Xuezhi Hao, Puyuan Xing, Jun-Ling Li
Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives. Cancer innovation 2 (1) (2023)
Si-Yu Lei, Hai-Yan Xu, Hong-Shuai Li, Ya-Ning Yang, Fei Xu, Jun-Ling Li, Zhi-Jie Wang, Pu-Yuan Xing, Xue-Zhi Hao, Yan Wang
Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer. Thoracic cancer (2023)
Boyang Sun, Tian Qiu, Xiaoling Zeng, Jianchun Duan, Hua Bai, Jiachen Xu, Jin Li, Jun-Ling Li, Xuezhi Hao, Yutao Liu, Lin Lin, Hongyu Wang, Xin Zhang, Jia Zhong, Jie Wang, Jianming Ying, Zhijie Wang
Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors. Cancer research communications 3 (4) (2023)
Fei Xu, Jun-Ling Li, Pu-Yuan Xing, Yutao Liu, Yan Wang
Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain-only relapse versus synchronous extracranial relapse. Cancer medicine (2023)
Fei Xu, Heng-Chi Chen, Hai-Yan Xu, Jun-Ling Li, Xuezhi Hao, Pu-Yuan Xing, Jianming Ying, Yan Wang
Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrences. Thoracic cancer 13 (22) (2022)
Yan Li, Ziyi Xu, Shou-Zheng Wang, Yi-Xiang Zhu, Di Ma, Yuxin Mu, Jian-Ming Ying, Jun-Ling Li, Pu-Yuan Xing
Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA. Thoracic cancer 13 (15) (2022)
Ziyi Xu, Xuezhi Hao, Ke Yang, Qi Wang, Jing Wang, Lin Lin, Fei Teng, Jun-Ling Li, Puyuan Xing
Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study. Journal of cancer research and clinical oncology 148 (11) (2022)
Dantong Sun, Puyuan Xing, Jun-Ling Li
PD-L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR-mutant non-small cell lung cancer cells. Cancer innovation 1 (4) (2022)
Fei Teng, Puyuan Xing, Ke Yang, Lizhen Gao, Zhongqiu Tian, Jun-Ling Li
Apatinib as maintenance therapy following standard first-line chemotherapy in extensive disease small cell lung cancer: A phase II single-arm trial. Thoracic cancer 13 (4) (2022)
Tongji Xie, Zhenghao Liu, Yan Li, Shou-Zheng Wang, Yixin Zhai, Fei Teng, Xuezhi Hao, Yan Wang, Hongyu Wang, Xin Zhang, Xi Wu, Jianming Ying, Jun-Ling Li, Ye Zhang, Yuefei Deng, Pu-Yuan Xing
Evolutionary characteristics and immunological divergence of lung and brain metastasis lesions in NSCLC. Molecular cancer research : MCR (2022)
Ziyi Xu, Xuezhi Hao, Lin Lin, Jun-Ling Li, Puyuan Xing
Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation. Thoracic cancer 12 (16) (2021)
Shouzheng Wang, Tongji Xie, Xuezhi Hao, Yan Wang, Xingsheng Hu, Lin Wang, Yan Li, Jun-Ling Li, Pu-Yuan Xing
Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. Thoracic cancer 12 (19) (2021)
Dantong Sun, Fei Teng, Puyuan Xing, Jun-Ling Li
ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer. Molecular medicine (Cambridge, Mass.) 27 (1) (2021)
Teng Li, Shouzheng Wang, Jianming Ying, Yan Wang, Xing-Sheng Hu, Xuezhi Hao, Ziyi Xu, Puyuan Xing, Jun-Ling Li
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Thoracic cancer 12 (21) (2021)
Puyuan Xing, Mengzhao Wang, Jun Zhao, Wei Zhong, Yujia Chi, Ziyi Xu, Jun-Ling Li
Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy. Thoracic cancer 12 (20) (2021)
Ziyi Xu, Teng Li, Xingsheng Hu, Xuezhi Hao, Puyuan Xing, Jun-Ling Li
Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC). Thoracic cancer 12 (17) (2021)
Tongji Xie, Zihua Zou, Chengcheng Liu, Yi-Xiang Zhu, Ziyi Xu, Le Wang, Jun-Ling Li, Pu-Yuan Xing
Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis. Evidence-based complementary and alternative medicine : eCAM 2021 (2021)
Zihua Zou, Xuezhi Hao, Cuiying Zhang, Haojing Li, Guilan Dong, Yumei Peng, Kewei Ma, Ye Guo, Li Shan, Yan Zhang, Li Liang, Yangchun Gu, Pu-Yuan Xing, Jun-Ling Li
Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China. Thoracic cancer (2021)
Jinyao Zhang, Yan Wang, Ziling Liu, Lin Wang, Yu Yao, Yutao Liu, Xue Zhi Hao, Jianyang Wang, Pu-Yuan Xing, Jun-Ling Li
Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases. Thoracic cancer (2021)
Li-Ling Huang, Xing-Sheng Hu, Yan Wang, Jun-Ling Li, Hong-Yu Wang, Peng Liu, Jian-Ping Xu, Xiao-Hui He, Xue-Zhi Hao, Pei-Di Jiang, Yu-Tao Liu, Jian Luo, Sheng-Yu Zhou, Jin-Wan Wang, Jian-Liang Yang, Yan Qin, Peng Yuan, Lin Lin, Yuan-Kai Shi
Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients. Thoracic cancer 12 (13) (2021)
Puyuan Xing, Shouzheng Wang, Qiang Wang, Di Ma, Xuezhi Hao, Mengzhao Wang, Yan Wang, Li Shan, Tao Xin, Li Liang, Hongge Liang, Yang Du, Zhaohui Zhang, Jun-Ling Li
Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China. Targeted oncology 14 (3) (2020)
Yiying Guo, Lin Yang, Li Liu, Jiacong Wei, Fei Teng, Jinyao Zhang, Yi-Xiang Zhu, Puyuan Xing, Jun-Ling Li
Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection. Thoracic cancer 11 (10) (2020)
Jiacong Wei, Li Liu, Yiying Guo, Jinyao Zhang, Xin Wang, Jiyan Dong, Puyuan Xing, Jianming Ying, Lin Yang, Jun-Ling Li
Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer. Thoracic cancer 12 (1) (2020)
Yuxin Mu, Xuezhi Hao, Puyuan Xing, Xingsheng Hu, Yan Wang, Teng Li, Jinyao Zhang, Ziyi Xu, Jun-Ling Li
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. Journal of cancer research and clinical oncology 146 (9) (2020)
Di Ma, Yan Zhang, Puyuan Xing, Xuezhi Hao, Mengzhao Wang, Yan Wang, Li Shan, Tao Xin, Hongge Liang, Yang Du, Zhaohui Zhang, Li Liang, Jun-Ling Li
Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib. Thoracic cancer 10 (5) (2019)
P Xing, Y Mu, X Hao, Y Wang, Jun-Ling Li
Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 21 (10) (2019)
Puyuan Xing, Fan Zhang, Guoqiang Wang, Yu Xu, Chengcheng Li, Shouzheng Wang, Yiying Guo, Shangli Cai, Yan Wang, Jun-Ling Li
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. Journal for immunotherapy of cancer 7 (1) (2019)
Shouzheng Wang, Puyuan Xing, Ke Yang, Xuezhi Hao, Di Ma, Yuxin Mu, Jun-Ling Li
Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. Thoracic cancer 10 (6) (2019)